|
|
Article: Hoechst Marion Roussel's Arava(TM) Recommended for Approval By FDA Advisory Committee for Treatment of Adult Rheumatoid Arthritis (RA)
- Article from:
- PR Newswire
- Article date:
- August 7, 1998
CopyrightCOPYRIGHT 1998 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Provides Hope for More Than Two Million RA Patients
in Need of New, Effective Treatments
KANSAS CITY, Mo., Aug. 7 /PRNewswire/ -- Hoechst Marion Roussel, the pharmaceutical company of Hoechst AG, announced today that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) has unanimously recommended approval of Arava(TM) (leflunomide) for the treatment of active rheumatoid arthritis (RA) in adults. If approved, Arava will be the first new disease modifying agent specifically developed for the treatment of rheumatoid arthritis -- a potentially crippling disease that affects more than 2 million Americans ...